| Literature DB >> 35955712 |
Ivana Jarak1, Inês Silva1, Cátia Domingues1,2,3, Ana Isabel Santos1, Francisco Veiga1,2, Ana Figueiras1,2.
Abstract
The fast advancement in nanotechnology has prompted the improvement of numerous methods for the creation of various nanoscale composites of which nanofibers have gotten extensive consideration. Nanofibers are polymeric/composite fibers which have a nanoscale diameter. They vary in porous structure and have an extensive area. Material choice is of crucial importance for the assembly of nanofibers and their function as efficient drug and biomedicine carriers. A broad scope of active pharmaceutical ingredients can be incorporated within the nanofibers or bound to their surface. The ability to deliver small molecular drugs such as antibiotics or anticancer medications, proteins, peptides, cells, DNA and RNAs has led to the biomedical application in disease therapy and tissue engineering. Although nanofibers have shown incredible potential for drug and biomedicine applications, there are still difficulties which should be resolved before they can be utilized in clinical practice. This review intends to give an outline of the recent advances in nanofibers, contemplating the preparation methods, the therapeutic loading and release and the various therapeutic applications.Entities:
Keywords: biomedicine; drug loading; nanofibers; nanotechnology; therapeutic applications
Mesh:
Substances:
Year: 2022 PMID: 35955712 PMCID: PMC9368923 DOI: 10.3390/ijms23158581
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1The overview of techniques for nanofiber fabrication. Some of the many possible nanofiber morphologies are presented in the central part: (1) Core-shell NFs obtained by microsol electrospinning loaded with liposomes (yellow arrow). Adapted from [9]. Copyright © 2020, The Author(s) under CCBY licence. (2) Janus NFs loaded with AgNP and ciprofloxacin prepared by side-by-side electrospinning. Reprinted from [10] with permission from Elsevier. (3) Hierarchical shish-kebab core-shell NF prepared for growth factor delivery. Adapted with permission from [11]. Copyright 2020 American Chemical Society. (4) and (5) Aligned and random oriented NFs. Adapted from [12] under CC BY 4.0. (6) 3D nanofibrous construct prepared by electrospinning and electrospraying. Reprinted from [13], with permission from Elsevier. In the innermost part, therapeutic agents that can be delivered by nanofibers are presented. * Reprinted with permission from [14] the Royal Society of Chemistry. ** Reprinted with permission from [15]. Copyright 2013, American Chemical Society.
Figure 2The self-assembly of Dox-polypeptide conjugates (FDPC-NPs) and the morphologic transformation of the acid-responsive FDPC-NPs in vitro and in vivo. Change in tumor site pH causes disintegration of micelle shell (1) and subsequent assembly of nanofibers (2) driven by π–π stacking, leading to long-term drug retention in the tumor [27]. Reprinted with permission from [27], Copyright 2022, Ivyspring International Publisher.
Figure 3Characterization of PLGA/PELA2500/CiH electrospun membranes with different contents of the second component PELA2500. (A–C) Cross-sections of PLGA/PELA2500/CiH membranes: (A) PLGA/PELA2500 (90/10); (B) PLGA/PELA2500 (93/7); (C) PLGA/PELA2500 (95/5). (D) In vitro drug release profiles of PLGA/PELA2500/CiH membranes. (E) Changes in the absorption time of PLGA/PELA2500/CiH membranes the values of the contact angles of the membranes. (F) Changes in the fiber diameter ratio of PLGA/PELA2500/CiH membranes. © 2020 The Authors. Published by Elsevier B.V, under CC-BY-NC-ND license.
Overview of the external stimuli used in design of smart nanofibers.
| Polymer | Solvent | Therapeutic Agent | Fabrication | Fiber Diameter | Architecture | Therapeutic Outcome | Ref |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Eudragit® RS 100 PMMA | DMF | Octenidine | Single nozzle electrospinning | 134–168 nm | Single mesh | Reduced in vitro bacterial colony formation | [ |
| PCL/PNIPAAM | TFE | Doxycycline hyclate | Single nozzle electrospinning followed by mesh immersion and UV crosslinking | 275–490 nm | Core-crosslinked shell mesh | Reduced in vitro bacterial colony formation | [ |
| P(NIPAAm- | H2O CH2Cl2/DMF | Light-assisted co-axial electrospinning | 1400 nm | Crosslinked core-shell | Enhanced drug penetration in soft tissues by NIR-light assistance | [ | |
| poly(NIPAAM-co-AAh)/PEGDMA | Ethanol TFE | Bovine serum albumin Dexamethasone phosphate | EHD side-by-side co-jetting followed by UV crosslinking | ~1000 nm | Bicompartmental nanofibers | - | [ |
| PGS/PCL | CH2Cl2/ Ethanol | NP-encapsulated cefazolin and ceftriaxone | Single nozzle electrospinning followed by printing of electrically conductive pattern | 350–1100 nm | Elastic sheets | Reduced in vitro bacterial colony formation | [ |
|
| |||||||
| PVA/p(4VP- | H2O | Rose Bengal | Single nozzle electrospinning followed by chemical vapor deposition | 580 nm | Core-coated mats | In vitro antiproliferative activity against cancer cells (U87MG) | [ |
| aPLA/HA | CH2Cl2/DMF | Interleukin-4 pDNA-loaded liposome Nerve growth factor | Microsol electrospinning followed by chemical grafting of liposomes | 550–570 nm | Oriented core-shell fiber scaffolds | Reduced in vivo inflammatory response, increased nerve repair and recovery of motor function | [ |
|
| |||||||
| PEO/PCL and redox responsive c-6A PEG-PCL/6A PEG-PCLSH NG | CH2Cl2 H2O | BMP-2 | Co-axial electrospinning | 220–340 nm | Core-shell | In vitro stem cell osteogenesis differentiation. In vivo mandible bone reconstruction | [ |
|
| |||||||
| coPEA 8-[L-Phe-6] 0.95–[L-Leu-6]0.05/ | H2O CH2Cl2/C6H12 | a-chymotrypsin | Colloid electrospinning | 375–1380 nm | Single scaffolds | - | [ |
| HA-SH PEO | H2O | Tenofovir | Co-axial electrospinning | 75 nm | Core-shell scaffolds | In vitro anti-HIV effect | [ |
| P18-PLGVRGRGD | H2O | P18 | Gelatinase-triggered in situ formation | 30 nm | Fibrous superstructures | Improved photoacoustic tumor imaging and therapeutic efficacy | [ |
|
| |||||||
| PNIPAM/ Au nanorods | DMF/THF | Camptothecin | Single nozzle electrospinning followed by high temperature cross-linking | 600–700 nm | Single scaffolds | In vitro decreased viability of malignant glioma cells (U-87 MG) | [ |
| PVA/PVP-FeOOH | H2O | Methylene blue | Co-axial electrospinning | 580 nm | Core-shell mat | - | [ |
| PLLA/P(NIPAAm-co-PNIPMAAm) AuNR hydrogel | CHCl3/DMF | Rhodamine B | Single nozzle electrospinning followed by pillow assembly and interface UV-crosslinking | Nanostructured pillow composed of NF membrane and hydrogel core | [ | ||
|
| |||||||
| PVA/IONP | H2O | Acetaminophen | Infusion gyration followed by drug adsorption | 100−300 nm | Single mats of beaded fibers | - | [ |
|
| |||||||
| P(VDF-TrFE) | DMF/THF | Crystal violet poly(L-lysine)-Vivotag-645 | Single nozzle electrospinning | 70–500 nm | Nanofibrous membranes | - | [ |
|
| |||||||
| PNVCL/EC Eudragit L100 | Ethanol | Ketoprofen | Twin-jet electrospinning | 350–670 nm | Thermo- and pH-sensitive hybrid mats | - | [ |
| PLGA/ IONP | HFIP | Bortezomib | Single nozzle electrospinning followed by functionalization | 600 nm | Not-like nanofibers | In vitro apoptosis in breast cancer cells (4T1) | [ |
Abbreviations: PNIPAM: Poly(N-isopropylacrylamide); PCL: polycaprolactone; TFE: 2,2,2 trifluoroethanol; NVCL: N-vinylcaprolactam; MAA: methacrylic acid; DMAC: N,N-Dimethylacetamide; EHD: electrohydrodynamic; poly(NIPAM-co-Aah): poly(N-isopropylacrylamide-co-allylamine hydrochloride); PEGDMA: poly(ethylene glycol) dimethacrylate; BMP-2: bone morphogenetic protein 2; PEO: Polyethylene oxide; c-6A PEG-PCL/6A PEG-PCLSH NG: polyethyleneglycol-polycaprolactone/6 arm polyethyleneglycol-polycaprolactone-sulfhydryl nanogel; P(NIPAAm-co-NIPMAAm): poly(N-isopropylacrylamide-co-N-isopropylmethacrylamide); PLCL: poly-l-lactide-co-caprolactone; DMF: dimethylformamide; P(VDF-TrFE): poly(vinylidene fluoride-trifluroethylene); PVA: polyvinyl alcohol; p(4VP-co-EGDMA): poly(4-vinylpyridine-co-ethylene glycol dimethacrylate); PNVCL: poly(N-vinylcaprolactam); EC: ethyl cellulose; coPEA: copoly(ester amide); C6H12: cyclohexane; aPLA: amino polylactic acid; HA: sodium hyaluronate; HA-SH: thiolated HA; PVP: polyvinylpyrrolidone; PLGA: poly(D,L-lactide-co-glycolide); HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol; NP: nanoparticle.
Figure 4Combination neuron therapy by NF: (A) Construction of oriented fiber scaffold loaded with nerve growth factor by microsol electrospinning is followed by condensation with pDNA-loaded liposomes. (B) Morphology of different NF scaffolds (aP: amino PLA NF; MSaP: aPLA microsol fibers; MSaP-aL/p: MSaP conjugated with pDNA-loaded liposomes where the yellow arrow indicates the position of liposome). (C) Evaluation of motor function recovery by BBB and IPT scores. * p < 0.5, ** p < 0.01. Adapted from [9]. Copyright © 2020, The Author(s) under CCBY licence.
Nanofiber systems used for delivery of small therapeutic drugs.
| Polymer | Therapeutic Agent | Functionalization | Fabrication | Architecture | Administration Route | Therapeutic Outcome | Ref |
|---|---|---|---|---|---|---|---|
| Amphiphilic peptides | Liver X receptor agonist GW3965 | ApoA1-targeting peptide | Self-assembly | Individual NFs with secondary β-sheet structure | Intravenous | Reduced plaque burden | [ |
| Amphiphilic peptides | Taxol | FGL | Self-assembly | NFs hydrogel | Intraspinal microinjection post-SCI | In vitro and in vivo neurite elongation. Decreased inflammatory response and neurobehavioral recovery in vivo | [ |
| PLA | Paclitaxel | - | Single nozzle | NF membrane | - | Inhibition of cancer cells growth (HCT-116) | [ |
| PCL | Lipophosphonoxin | - | Single nozzle | NF scaffold | NF wound dressing | Reduced | [ |
| PVA/ | Dox-loaded PCL-PEG micelle | Folate-decorated micelles | Coaxial electrospinning | Core-shell NFs | Localized implant | In vitro and in vivo antitumor effect against mammary tumor | [ |
| PCL/PVP | Multi-walled carbon nanotubes 5-fluorouracil | - | Coaxial electrospinning | Core-shell NF | - | In vitro cytotoxicity against HeLa cervical tumor cells | [ |
| PLA/PLGA | Aceclofenac or insulin | - | Core electrospinning followed by sheet electrospinning | Twisted core yarn coated with drug-loaded sheet | Surgical sutures | Sustained drug release attenuated skin inflammation in in vivo animal model | [ |
| PCL | pSiNP/drug, enzyme or RNA aptamer pSiNP/levofloxacin | - | Airbrush spray nebulization. Single nozzle electrospinning | Aligned NFs NF mat | - | Directional growth of neuronal cells | [ |
| PVA | Liposomes loaded with tenofovir disoproxil fumarate and emtricitabine | - | Single nozzle | NF mat | - | [ |
Abbreviations: CDN: cyclic-dinucleotide; PDA: polydiacetylenic; PAA: poly(acrylic acid); rGO: reduced graphene oxide; POSS: functional polyhedral oligomeric silsesquioxane; PVA: Poly-(vinyl alcohol); FGL: neural cell adhesion molecule motive; SCI: spinal cord injury.
Nanofiber systems used for the delivery of therapeutic protein and peptides.
| Polymer | Therapeutic Agent | Fabrication | Architecture | Administration Route | Therapeutic Outcome | Ref |
|---|---|---|---|---|---|---|
| Q11 self-assembly domain | Influenza acid polymerase epitope | Self-assembly | Individual NFs | Intranasal Subcutaneous | Reduced viral load in the lungs 6 weeks after 2nd vaccination | [ |
| PEG-Q11R9 | CDN mucosal adjuvants | Self-assembly | Individual NFs | Sublingual | Activation of dendritic cells in the draining lymph nodes | [ |
| SF/PCL/PVA | BMP2 CTGF | Coaxial electrospinning followed by layer-by-layer deposition | Multilayer core-shell NF | Implant | In vitro and in vivo temporal control of GF release | [ |
| PLGL/CNC | Neurotensin | Single nozzle electrospinning | Composite NF membrane | Wound patch | Accelerated skin regeneration | [ |
| PCL | Pexiganan | Single nozzle electrospinning followed by hydrolysis | NF mats | - | In vitro antimicrobial activity on gram-positive and negative bacteria | [ |
| PAA/rGO β-cyclodextrin | Insulin | Single nozzle electrospinning | Hydrogel-like fiber mats | Buccal Eye cornea | Ex vivo delivery via eye | [ |
| PCL | Bacteriophage capsid | Single nozzle electrospinning followed by bacteriophage conjugation | Elastic NF mat | - | In vitro bactericidal activity ( | [ |
Abbreviations: CDN: cyclic-dinucleotide; PAA: poly(acrylic acid); rGO: reduced graphene oxide; SF: BMP2: bone morphogenetic protein 2; CTGF: connective tissue growth factor; SK: silk fibroin; CNC: cellulose nanocrystals.
Figure 5Multilayer NF loaded with growth factors for bone healing ((SF/PCL)1:5/PVA-LBL20). (1) Core-shell NFs with MBP2-loaded core is functionalized by successive layers of chitosan and the second growth factor, CTGF. (2) Time-controlled release of growth factors after intracranial implantation. (3) Temporal development of microvasculature formation. * p < 0.5 Adapted with permission from [144]. Copyright 2019 American Chemical Society.
Nanofiber systems used for the delivery of polynucleotides.
| Polymer | Therapeutic Agent | Functionalization | Fabrication | Architecture | Administration Route | Therapeutic Outcome | Ref |
|---|---|---|---|---|---|---|---|
| palmitoyl-GGGAAAKRK peptide amphiphile | siRNA | - | Self-assembly | Individual NFs | Intra-tumoral administration | Extended survival of glioblastoma bearing mice | [ |
| PDA | siRNA | - | Photopolymerization | Individual NFs | Intraperitoneal | In vitro and in vivo transfection of cancer cells and oncogene silencing | [ |
| pDNA-PEI | pDNA polyplex | Au nanorods | Coaxial electrospinning | Nanofiber mats | - | Improved in vitro transfection | [ |
| PVA | pDNA-CHAT polyplex | Cell penetrating CHAT peptide | Single nozzle electrospinning followed by DNAsoak-loading | Crosslinked nanofibers | - | Improved in vitro transfection | [ |
| Virus-inspired polypeptide gene vector capped with lipophilic tail | pDNA | tetraphenylethene | Self-assembly | Individual NFs | - | In vitro transfection of wide cell range, including stem cells | [ |
| PCL/gelatin | miRNA polyplex | - | Dual power electrospinning | Bilayer electrospun membranes |
| Improved in vitro osteogenic differentiation of human-induced pluripotent stem cells | [ |
| PCL | LNPs loaded with CRISPR-Cas9 RNP complex | Biomimetic MSCM coating CXCL12 chimokine | Single nozzle electrospinning | Fragmented nanofibrils with biomimetic coating | Intra bone-marrow injection | Reduced human leukemic burden in mice | [ |
|
| |||||||
| HA/aPLA | pDNA-loaded aLiposome nerve GF | - | Microsol Electrospinning followed by chemical grafting of pDNA-aLiposome | Oriented core-shell NF | Implantation | Reduced in vivo inflammatory response, increased nerve repair and recovery of motor function | [ |
Abbreviations: CDN: cyclic-dinucleotide; PDA: Polydiacetylenic; PAA: poly(acrylic acid); rGO: reduced graphene oxide; POSS: functional polyhedral oligomeric silsesquioxane; PVA: Poly-(vinyl alcohol); GF: growth factor; aPLA: aminated PLA.
Figure 6Injectable biomimetic nanofiber formulation for acute myeloid leukemia treatment: (1) PCL nanofibril coated with mesenchymal stem cell membrane (MSCM) loaded with cytokine CXCL12α and lipid nanoparticles-CRISPR/Cas9 (LNP-Cas9) complex. (2) Images of naked NF and MSCM-coated NF. (3) Biodistribution of MSCM-NF/LNP-Cas9 after injection into the bone marrow of right tibia indicates prolonged localization in tibia when compared with LNP-Cas9. (4) Leukemia stem cells exhibit reduced colony formation after treatment with therapeutic MSCM-NF/LNP-Cas9. **** p < 0.0001. Adapted from [158]. Copyright © 2021, The Author(s) under CCBY 4.0 license.
Nanofiber systems used for delivery of polynucleotides.
| Polymer | Therapeutic Cell | Fabrication | Architecture | Therapeutic Outcome | Ref |
|---|---|---|---|---|---|
| β-chitin | ADSC | Chemically from natural sources | NF hydrogel | Improved in vivo wound healing | [ |
| α-chitin | BMSC | Chemically from natural sources | NF hydrogel | Improved in vivo wound healing | [ |
| PCL | BMSC, ADSC, UCSC | Fused deposition modeling | NF directed scaffolds | Enhanced in vitro proliferation and osteogenic potency | [ |
| PCA/gelatin PLGA/gelatin | MSC, ESC | Electrospinning followed by electrospraying | Injectable NF microspheres | In vitro neural differentiation of ESC | [ |
| Amphiphilic peptides | MuSC, VEGF, bFGF | Self-assembly followed by annealing and gelation | Injectable liquid crystalline NF gel | Enhanced engraftment of transplanted MuSCs | [ |
| PCL-PS/MeHA | hNSC | Axial electrospinning followed by gel coating and crosslinking | SLIDING NFs | Prolonged survival of cells | [ |
| PLA/collagen | MSC | Simultaneous co-axial cell electrospraying and polymer electrospinning | Cell-loaded NFs | Enhanced bone regeneration | [ |
| Chitosan/PVA/SF | BMSC-derived keratinocytes | Single nozzle electrospinning followed by crosslinking | NF mat | Improved wound healing and skin regeneration | |
| PLA | ADSC | Single nozzle electrospinning followed by fragmentation and mineralizarion | Composite spheroids based on mineralized NF | Sustained ADSC viability and enhanced expression of osteogenic genes | [ |
| PCL | Melanocyte | Single nozzle electrospinning followed by platelet soaking | Functionalized NF mats | Sustained melanocyte growth under the influence of GFs secreted by platelets Stimulated melanin synthesis for vitiligo treatment | [ |
| SF | Wharton’s jelly MSC | Single nozzle electrospinning | Crosslinked NF 3D mat | Improved in vivo wound healing | [ |
| SF | BASC | Salt sinking followed by CF growth and decullarization | ECM-coated NF mat | In vitro differentiation of BASC into CF | [ |
| Collagen/PVA | ADSC | Single nozzle electrospinning | NF 3D mat | In vitro differentiation of ADSC into chondrogenic cells | [ |
Abbreviations: SC: stem cell; AD: adipose derived; BM: bone marrow; UC: umbilical cord; MSC: mesenchymal SC; ESC: embryonal SC; Mu: muscle; VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor; PLCL: Poly(lactide-co-ε-caprolactone); Gel-MA: gelatin-methacrylate; Me-HA: methylacrylated hyaluronic acid; hNSC: human neural SC; BASC: brown adipose SC; CF: cardiac fibroblasts; ECM: extracellular matrix; CF: cardiac fibroblasts; SF: silk fibroin.
A summary of the registered clinical trials using the term “nanofiber.” Data was collected from the clicaltrial.gov database based on a search performed on the 27 June 2022.
| NCT Number | Phase | Status | Condition(s) | Intervention(s) |
|---|---|---|---|---|
| NCT 04325789 | Not Applicable | Recruiting | Rotator Cuff Tears | Nanofiber scaffold |
| NCT 03690960 | Not Applicable | Unknown | Necrosis, Pulp | Electrospun TAP nanofibers |
| NCT 03242291 | Not Applicable | Unknown | Marginal Integrity of Hydroxyapatite Nanofiber Reinforced Flowable Composite | Conventional resin-based flowable composite. Hydroxyapatite Nanofiber reinforced flowable composite |
| NCT 03264105 | Not Applicable | Unknown | Retention Rate of Flowable Composite in Demineralized Pits and Fissure | Conventional resin-based flowable composite. Hydroxyapatite Nanofiber reinforced flowable composite |
| NCT 04867265 | Not Applicable | Completed | Ventilation During Resuscitation | Mouth-to-mouth ventilation |
| NCT 04870736 | Withdrawn | Basic Life Support Ventilation | Mouth-to-mouth ventilation | |
| NCT 02237287 | Early Phase 1 | Terminated | Wounds|Pressure Ulcer | Wound dressing with VAC and sNAG without anti-aggregation |
| NCT 02680106 | Not Applicable | Completed | Wound of Skin | Experimental: SPINNER. Active Comparator: JELONET/IBU Biatain |
Abbreviations: IBU: Biatain dressing used for split-skin donor-site wounds; JELONET: gauze dressing used for split-skin donor-site wounds; sNAG: poly-N-acetyl glucosamine nanofibers; SPINNER: a hand-held, portable electro-spinning device that produces personalized in-situ nanofiber dressings for the treatment of external burns and wounds; TAP: a triple antibiotic mixture consisting of ciprofloxacin (CIP), metronidazole (MET) and minocycline (MINO); VAC: vacuum-assisted closure.